This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Data Presented At ATTD 2014 Suggest T:slimA® Insulin Pump Faster To Train With Fewer Use Errors Than Competition

In another presentation at ATTD, data was presented from a preliminary analysis of self-reported outcomes of people using the t:slim Insulin Pump.  A subset of t:slim Pump users self-reported their HbA1c, a three-month average blood glucose measurement (n=289).  t:slim Pump users who had previously used a different insulin pump (n=211) saw an HbA1c decrease of 0.2 percentage points (p< 0.001, average t:slim Pump use approximately 6 months). People who had never used an insulin pump before (n=78), reported an HbA1c decrease of 0.9 percentage points (p<0.001, average t:slim Pump use approximately 5 months).

These data were presented as part of the Tandem-sponsored symposium, Optimizing Insulin Pump Use through Human Factors Research, moderated by Dr. Timothy Bailey. Human Factors Research is a scientific discipline that uses evidence-based data to optimize a device or system to the intended user through iterative usability testing and design refinement. Tandem's t:slim Pump was one of the first insulin pumps to use extensive Human Factors Research in its development.  It is the first insulin pump with a color touch screen, rechargeable battery, and USB-connectivity, and it holds up to 300 units of insulin.

About Tandem Diabetes Care, Inc. Tandem Diabetes Care, Inc. ( www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company manufactures and sells the t:slim Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, and the first and only insulin pump with a high resolution, color touch screen. Tandem is based in San Diego, California.

Forward Looking StatementThis press release includes forward-looking statements relating to Tandem's t:slim® Insulin Pump, including the results and conclusions from research studies comparing the t:slim Pump to other currently marketed insulin pumps, and the properties and potential benefits of using the t:slim Pump as compared to multiple daily injections. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including: risks that current and past results of research studies may not be indicative of results of future research studies or of actual user experience; the potential that newer products that compete with the t:slim Pump, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the t:slim Pump obsolete or less desirable; Tandem's ability to manufacture products in commercial quantities at an acceptable cost and while maintaining quality standards;  and other risks identified in Tandem's Registration Statement on Form S-1. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update any forward-looking statement in this press release.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslim and #tconnect. Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.

t:slim, t:connect and Tandem Diabetes Care are registered trademarks of Tandem Diabetes Care, Inc. Medtronic and Minimed are registered trademarks, and Revel is a trademark, of Medtronic, Inc.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs